-+ 0.00%
-+ 0.00%
-+ 0.00%

Skye Reports Phase 2a Extension Results Showing 22.3% Weight Loss At 52 Weeks With Nimacimab And Semaglutide Combination

Benzinga·02/02/2026 12:22:08
Listen to the news
  • 22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses
  • Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantage
  • Strong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period